Abstract
The central endocannabinoid system is a neuroactive lipid signalling system in the brain which acts to control neurotransmitter release. The expression patterns of this system throughout limbic regions of the brain ideally situate it to exert regulatory control over emotional behaviour, mood and stress responsivity. A growing body of evidence unequivocally demonstrates that deficits in endocannabinoid signalling may result in depressive and anxiogenic behavioural responses, while pharmacological augmentation of endocannabinoid signalling can produce both antidepressive and anxiolytic behavioural responses. The aim of this review is to summarize current knowledge of the role of the endocannabinoid system in the etiology and treatment of mood and anxiety disorders, such as depression, anxiety and post-traumatic stress disorder. Collectively, both clinical and preclinical data argue that cannabinoid receptor signalling may be a realistic target in the development of a novel class of agent for the pharmacotherapy of mood and anxiety disorders.
CNS & Neurological Disorders - Drug Targets
Title: The Endocannabinoid System and the Treatment of Mood and Anxiety Disorders
Volume: 8 Issue: 6
Author(s): Matthew N. Hill and Boris B. Gorzalka
Affiliation:
Abstract: The central endocannabinoid system is a neuroactive lipid signalling system in the brain which acts to control neurotransmitter release. The expression patterns of this system throughout limbic regions of the brain ideally situate it to exert regulatory control over emotional behaviour, mood and stress responsivity. A growing body of evidence unequivocally demonstrates that deficits in endocannabinoid signalling may result in depressive and anxiogenic behavioural responses, while pharmacological augmentation of endocannabinoid signalling can produce both antidepressive and anxiolytic behavioural responses. The aim of this review is to summarize current knowledge of the role of the endocannabinoid system in the etiology and treatment of mood and anxiety disorders, such as depression, anxiety and post-traumatic stress disorder. Collectively, both clinical and preclinical data argue that cannabinoid receptor signalling may be a realistic target in the development of a novel class of agent for the pharmacotherapy of mood and anxiety disorders.
Export Options
About this article
Cite this article as:
Hill N. Matthew and Gorzalka B. Boris, The Endocannabinoid System and the Treatment of Mood and Anxiety Disorders, CNS & Neurological Disorders - Drug Targets 2009; 8 (6) . https://dx.doi.org/10.2174/187152709789824624
DOI https://dx.doi.org/10.2174/187152709789824624 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Inflammatory and Anti-Allergy Drugs in Rhinosinusitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial (Thematic Issue: Cell Metabolism and Current Challenges in Drug Research)
Current Pharmaceutical Design Hypogonadotrophic Hypogonadism in Type 2 Diabetes, Obesity and the Metabolic Syndrome
Current Molecular Medicine Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry Gut Microbiota and Cardiovascular Disease: Symbiosis Versus Dysbiosis
Current Medicinal Chemistry Metabolic Aspects of Prion Diseases: An Overview
Current Drug Targets Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy Sibutramine Effects on Central Mechanisms Regulating Energy Homeostasis
Current Neuropharmacology Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets Obesity Modulation - The Role in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Etiology of the Metabolic Syndrome
Current Cardiology Reviews Chronopharmacology and Antimicrobial Therapeutics
Current Clinical Pharmacology Cognition and State Anxiety are Regulated by Thyroid Hormone Signaling
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Fibromyalgia
Current Rheumatology Reviews Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology The Complex Inter-Relationship Between Diabetes and Schizophrenia
Current Diabetes Reviews Pharmacological Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Potential of Gene Therapy for the Treatment of Pituitary Tumors
Current Gene Therapy Antidepressants: Current Strategies and Future Opportunities
Current Pharmaceutical Design Inflamm-ageing and senescence in gout: the tale of an old king’s disease.
Current Aging Science